Blockchain Registration Transaction Record

Kamada Projects 13% Revenue Growth for 2026, Driven by Plasma Therapies

Kamada Ltd. forecasts 13% revenue growth and 23% EBITDA growth for 2026, driven by plasma-derived therapies and expansion into new markets. Learn about their strategic plans.

This news matters because Kamada's projected growth reflects broader trends in the biopharmaceutical sector, where companies are increasingly focusing on self-sufficiency and diversification to mitigate risks like supply chain dependencies. For investors, the strong financial outlook, including double-digit revenue and EBITDA growth, signals potential stability and profitability in a competitive market. Patients and healthcare providers may benefit from Kamada's expansion of plasma-derived therapies, which are critical for treating rare diseases and immune disorders, potentially improving access and treatment options globally. Additionally, the company's move into plasma collection and distribution expansion could influence industry dynamics, encouraging more firms to invest in vertical integration to secure supply chains and reduce costs, ultimately impacting drug availability and pricing in regions like the Middle East and North Africa.